Abstract:Targeted therapy has dramatically improved the outcome of BRAF mutated melanoma patients. However, its response is usually brisk and lacks the durability of immunotherapy. Decisions about targeted therapy alone, immunotherapy alone, targeted therapy/immunotherapy combination or immunotherapy after targeted therapy require an oncologist to comprehensively evaluate multiple clinical factors. Here we report the sequential treatment of a BRAF positive metastatic melanoma patient with non-standard regimes due to practical reasons. A 75-year old male patient presented a black cauliflower-like mass on back and bilateral axillary lymph nodes enlargement. Postoperative pathologic examination confirmed a nodular malignant melanoma of 1.6 cm in diameter and 0.7 cm thick. NGS sequencing of the tumor revealed the canonical BRAF V600E mutation. As vemurafenib was the only approved melanoma targeted therapy drug in China at the time of diagnosis, it was administered (960 mg bid) as first-line therapy since September 2019 and the patient's response was confirmed by the significant reduction and softening of the left axillary node. One month later the node rapidly enlarged to 15 cm, and the blood scab fell off followed by pulsatile massive hemorrhage (~1000 mL). We performed an emergent angiograph and a transarterial embolization (TAE), aimed at selectively occluding the tumor artery by using gelatin sponge particle and coils. The hemorrhage was significantly reduced after TAE therapy and a left axillary residual cavity was formed. When the patient presented a progression of lymph node metastases, BRAF/MEK inhibitor combination was selected as the second-line therapy from December 2019. He received vemurafenib at a dose of 480 mg bid combined with cobimetinib 60mg qd (3 consecutive weeks every 28 days), the treatment was ongoing till disease progression in April 2020. Immunohistochemical analysis of the biopsy specimen demonstrated PD-L1 expression in 4% of tumor cells and immunotherapy was chosen as the third-line therapy. Sintilimab, a PD-1 antibody approved in China for the treatment of classical Hodgkin lymphoma, is undergoing clincial trials for multiple solid tumors including melanoma. Given the high cost of immunotherapy and the fact that Sintilimab is the only PD-1 inhibitor included in China's National Reimbursement Drug List, the patient started off-label use of Sintilimab and achieved partial response. In summary, our patient had an unconventional timeline of multiple therapies including surgery, TAE, targeted therapy and immunotherapy. His case demonstrated that meaningful clinical responses can be achieved with sequential targeted therapy/immunotherapy in BRAF-mutated metastatic melanoma and the novel PD-1 antibody Sintilimab is worth further investigation for its efficacy in metastatic melanoma. Citation Format: Yu Zhang, Xiaomo Li, Tonghui Ma, Baoshan Cao. Sequential targeted therapy and immunotherapy of a BRAF positive metastatic melanoma patient with BRAF inhibitor vemurafenib, MEK inhibitor cobimetnib and a novel PD-1 antibody Sintilimab [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 422.

Long-term Control of Melanoma Brain Metastases with Co-Occurring Intracranial Infection and Involuntary Drug Reduction During COVID-19 Pandemic: A Case Report.

In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways

Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors

Innv-19. Multimodal Therapy For Braf V600E Mutant Melanoma Brain Metastases: Characterization Of Chronological Treatment Strategies And Associations With Overall Survival

Negative Impact of COVID-19 Upon Primary Brain Tumor Care

A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases

Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking

Immune Checkpoint Inhibitors and Survival Outcomes in Brain Metastasis: A Time Series-Based Meta-Analysis

Delayed and Concurrent Stereotactic Radiosurgery in Immunotherapy-Naïve Melanoma Brain Metastases

Preoperative Treatment for Marginally Resectable Metastatic Melanoma: A Single Center Experience in China.

Patterns of Failure Outcomes for Combination of Stereotactic Radiosurgery and Immunotherapy for Melanoma Brain Metastases

Abstract 3785: Clinical and genomic characterization of melanoma brain metastases

Case report: Brain metastasis necrosis with immune checkpoint inhibitors plus chemotherapy for advanced non-small cell lung cancer

Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases.

Remission of Mucosal Melanoma of the Middle Ear and Petrous Temporal Bone and Reversal of Cranial Nerve Paresis Following Radiation and Single Agent Nivolumab: Clinical Capsule and Review of the Literature

Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis

Survival Benefits of Anti-PD-1 Therapy in Combination With Radiotherapy in Chinese Melanoma Patients With Brain Metastasis

Sequential targeted therapy and immunotherapy of a BRAF positive metastatic melanoma patient with BRAF inhibitor vemurafenib, MEK inhibitor cobimetnib and a novel PD-1 antibody Sintilimab.

Current and emerging options for patients with melanoma brain metastases

Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis

Insight into the management of patients with melanoma in times of the COVID-19 pandemic: A single-center experience